利扎布替尼长期治疗免疫性血小板减少症患者
这项正在进行的全球1/2期研究评估了利扎布替尼治疗免疫性血小板减少症(ITP)的长期疗效与安全性。16例应答者进入长期扩展研究继续接受利扎布替尼400 mg每日两次,中位治疗478天后69%仍在用药,93%患者超过一半的每月访视血小板计数≥50×10^9/L,治疗相关不良事件均为1-2级且短暂,无出血、血栓或严重不良事件。
要点
- 16例应答者中位治疗478天,11例(69%)继续接受利扎布替尼400 mg每日两次。
- 93%患者超过一半的每月访视血小板计数≥50×10^9/L。
- 治疗相关不良事件均为1或2级且短暂,无出血、血栓或严重不良事件。
核心结论
- 在长期扩展研究中继续利扎布替尼治疗,血小板应答持久且稳定,未出现新的安全性信号。
研究设计与样本
- 正在进行的全球1/2期研究,16例应答患者进入长期扩展研究继续接受利扎布替尼400 mg每日两次治疗。
主要发现
- 进入长期扩展研究时,所有患者中位血小板计数为87×10^9/L,单药治疗者(n=5)为68×10^9/L,接受合并ITP药物者(血小板生成素受体激动剂和/或糖皮质激素,n=11)为156×10^9/L。
- 中位治疗持续时间为478天(范围303-764天),16例中11例(69%)继续接受利扎布替尼治疗。
- 93%的患者超过一半的每月访视报告血小板计数≥50×10^9/L。
- 长期扩展研究期间血小板计数≥30×10^9/L和≥50×10^9/L的中位周数百分比分别为100%和88%。
- 5例患者停用合并ITP治疗,在停用合并ITP治疗后3至6个月维持中位血小板计数106×10^9/L。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.
引用
- Kuter DJ, Mayer J, Efraim M, et al. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood Adv. 2024. PMID: 38386978. doi:10.1182/bloodadvances.2023012044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。